Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25

Benzinga · 3d ago
Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $27 to $25.